Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 28Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Merkel Cell 1

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1methyl 5-aminolevulinate 1lifileucel 1efineptakin alfa 1cemiplimab 1balstilimab 1avelumab 1aldesleukin 1Rose Bengal 1Melphalan 1HhAntag691 1Cyclophosphamide 1Brentuximab Vedotin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × avelumab × Dermatologic × Clear all
NCT03089658 2019-10-09

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Merck KGaA, Darmstadt, Germany

Approved for marketing
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡